NCT04731272View on ClinicalTrials.gov

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Cystic FibrosisPancreatic InsufficiencyAbnormal Glucose ToleranceDiabetes
Interventions
DRUG

Dulaglutide 0.75Mg/0.5Ml Inj Pen

Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.

Trial Locations (2)

19104

RECRUITING

University of Pennsylvania, Philadelphia

80045

RECRUITING

Children's Hospital of Colorado, Aurora

All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Children's Hospital Colorado

OTHER

lead

University of Pennsylvania

OTHER